Clinical Trials
1,727 trialsNCT04704934 2026-05-27
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Daiichi Sankyo
Phase 3 Active not recruiting
NCT05052801 2026-05-27
FORTITUDE-101
Amgen
Phase 3 Completed
NCT05840341 2026-05-27
Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer
Fudan University
Phase 3 Completed
NCT06346392 2026-05-27
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Active not recruiting
NCT07218926 2026-05-27
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
GlaxoSmithKline
Phase 3 Recruiting
NCT07431281 2026-05-27
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT07609901 2026-05-27
PROTECT-Lynch
Radboud University Medical Center
Phase 3 Not yet recruiting
NCT00217737 2026-05-26
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03875235 2026-05-26
TOPAZ-1
AstraZeneca
Phase 3 Active not recruiting
NCT05064059 2026-05-26
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06997497 2026-05-26
KANDLELIT-012
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07284394 2026-05-26
PACHA-02
UNICANCER
Phase 3 Not yet recruiting
NCT07284849 2026-05-26
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Phase 3 Recruiting
NCT07522073 2026-05-26
DAWN-303
Incyte Corporation
Phase 3 Recruiting
NCT07606599 2026-05-26
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT02572141 2026-05-22
OPTICAL
Sun Yat-sen University
Phase 3 Active not recruiting
NCT04230187 2026-05-22
TRIBE-C
Sun Yat-sen University
Phase 3 Active not recruiting
NCT05208047 2026-05-22
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc.
Phase 3 Active not recruiting
NCT05239741 2026-05-22
MK-3475-C66
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06950385 2026-05-22
SERENTA
Rapamycin Holdings Inc.
Phase 3 Recruiting
NCT06998940 2026-05-22
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
Phase 3 Recruiting
NCT07582315 2026-05-22
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07594340 2026-05-22
HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
Sun Yat-sen University
Phase 3 Recruiting
NCT04588246 2026-05-20
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Phase 3 Terminated
NCT06593431 2026-05-20
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT06768164 2026-05-20
BYQoL-GC
Assistance Publique - Hôpitaux de Paris
Phase 3 Recruiting
NCT01150045 2026-05-19
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02200042 2026-05-19
Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable Localized Liver Cancer
NRG Oncology
Phase 3 Terminated
NCT05152147 2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
NCT05615818 2026-05-19
SAFIR-ABC10
UNICANCER
Phase 3 Recruiting
NCT05884255 2026-05-19
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT07488611 2026-05-19
PROGAIN
Soonchunhyang University Hospital
Phase 3 Recruiting
NCT07595276 2026-05-19
Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.
Taizhou Mabtech Pharmaceutical Co.,Ltd
Phase 3 Not yet recruiting
NCT07409272 2026-05-18
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Inc
Phase 3 Recruiting
NCT04927780 2026-05-15
PREOPANC-3
Erasmus Medical Center
Phase 3 Active not recruiting
NCT05863195 2026-05-15
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT07138846 2026-05-15
A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer
Lepu Biopharma Co., Ltd.
Phase 3 Not yet recruiting
NCT07562152 2026-05-15
MAPKeeper 301
Immuneering Corporation
Phase 3 Recruiting
NCT07591493 2026-05-15
ADJUPANET
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Not yet recruiting
NCT01269567 2026-05-14
GRECCAR 5
University Hospital, Bordeaux
Phase 3 Completed
NCT02514278 2026-05-14
GRECCAR12
University Hospital, Bordeaux
Phase 3 Completed
NCT04246177 2026-05-14
LEAP-012
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05652894 2026-05-14
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
Taizhou Hanzhong biomedical co. LTD
Phase 3 Active not recruiting
NCT06467357 2026-05-14
DESTINY-BTC01
AstraZeneca
Phase 3 Recruiting
NCT07265674 2026-05-14
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3 Recruiting
NCT07491445 2026-05-14
RASolute 303
Revolution Medicines, Inc.
Phase 3 Recruiting
NCT02997228 2026-05-13
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03017326 2026-05-13
PHITT
University of Birmingham
Phase 3 Active not recruiting
NCT03233711 2026-05-13
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04210115 2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting